Display options
Cite
Duffy AG, Ulahannan SV, Cao L, et al. A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. United European Gastroenterol J. 2015;3(5):453-61doi: 10.1177/2050640615583587.
Duffy, A. G., Ulahannan, S. V., Cao, L., Rahma, O. E., Makarova-Rusher, O. V., Kleiner, D. E., Fioravanti, S., Walker, M., Carey, S., Yu, Y., Venkatesan, A. M., Turkbey, B., Choyke, P., Trepel, J., Bollen, K. C., Steinberg, S. M., Figg, W. D., & Greten, T. F. (2015). A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. United European gastroenterology journal, 3(5), 453-61. https://doi.org/10.1177/2050640615583587
Duffy, A G, et al. "A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib." United European gastroenterology journal vol. 3,5 (2015): 453-61. doi: https://doi.org/10.1177/2050640615583587
Duffy AG, Ulahannan SV, Cao L, Rahma OE, Makarova-Rusher OV, Kleiner DE, Fioravanti S, Walker M, Carey S, Yu Y, Venkatesan AM, Turkbey B, Choyke P, Trepel J, Bollen KC, Steinberg SM, Figg WD, Greten TF. A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. United European Gastroenterol J. 2015 Oct;3(5):453-61. doi: 10.1177/2050640615583587. PMID: 26535124; PMCID: PMC4625750.
Copy Download .nbib Format: NLM
Share it on

United European Gastroenterol J. 2015 Oct;3(5):453-61. doi: 10.1177/2050640615583587.

A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib.

United European gastroenterology journal

A G Duffy, S V Ulahannan, L Cao, O E Rahma, O V Makarova-Rusher, D E Kleiner, S Fioravanti, M Walker, S Carey, Y Yu, A M Venkatesan, B Turkbey, P Choyke, J Trepel, K C Bollen, S M Steinberg, W D Figg, T F Greten

Affiliations

  1. Gastrointestinal Malignancies Section, Thoracic-GI Oncology Branch, Center for Cancer Research, National Cancer Institute, USA.
  2. Genetics Branch, Center for Cancer Research, National Institutes of Health, USA.
  3. Laboratory of Pathology, Center for Cancer Research, National Institutes of Health, USA.
  4. Radiology and Imaging Sciences, Center for Cancer Research, National Institutes of Health, USA.
  5. Molecular Imaging Department, Center for Cancer Research, National Institutes of Health, USA.
  6. Developmental Therapeutics Branch, Center for Cancer Research, National Institutes of Health, USA.
  7. Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, USA.
  8. Biostatistics and Data Management, Center for Cancer Research, National Institutes of Health, USA.

PMID: 26535124 PMCID: PMC4625750 DOI: 10.1177/2050640615583587

Abstract

BACKGROUND: Endoglin is an endothelial cell membrane receptor essential for angiogenesis and highly expressed on the vasculature of many tumor types, including hepatocellular carcinoma (HCC). TRC105 is a chimeric IgG1 anti-CD105 monoclonal antibody that inhibits angiogenesis and tumor growth by endothelial cell growth inhibition, ADCC and apoptosis, and complements VEGF inhibitors.

OBJECTIVE: The aim of this phase II study was to evaluate the efficacy of anti-endoglin therapy with TRC105 in patients with advanced HCC, post-sorafenib.

METHODS: Patients with HCC and compensated liver function (Childs-Pugh A/B7), ECOG 0/1, were enrolled to a single-arm, phase II study of TRC105 15 mg/kg IV every two weeks. Patients must have progressed on or been intolerant of prior sorafenib. A Simon optimal two-stage design was employed with a 50% four-month PFS target for progression to the second stage. Correlative biomarkers evaluated included DCE-MRI as well as plasma levels of angiogenic biomarkers and soluble CD105.

RESULTS: A total accrual of 27 patients was planned. However, because of lack of efficacy and in accordance with the Simon two-stage design, 11 patients were enrolled. There were no grade 3/4 treatment-related toxicities. Most frequent toxicities were headache (G2; N = 3) and epistaxis (G1; N = 4). One patient had a confirmed partial response by standard RECIST criteria and biologic response on DCE-MRI but the four-month PFS was insufficient to proceed to the second stage of the study.

CONCLUSIONS: TRC105 was well tolerated in this HCC population following sorafenib. Although there was evidence of clinical activity, this did not meet prespecified criteria to proceed to the second stage. TRC105 development in HCC continues as combination therapy with sorafenib.

Keywords: CD105; Hepatocellular carcinoma; angiogenesis; clinical trial; endoglin

References

  1. Invest New Drugs. 2014 Oct;32(5):851-9 - PubMed
  2. J Clin Oncol. 2013 Oct 1;31(28):3509-16 - PubMed
  3. PLoS One. 2012;7(12 ):e50920 - PubMed
  4. Clin Cancer Res. 2013 Dec 15;19(24):6957-66 - PubMed
  5. Clin Cancer Res. 2008 Apr 1;14 (7):1931-7 - PubMed
  6. Semin Oncol. 2012 Aug;39(4):493-502 - PubMed
  7. Clin Cancer Res. 2014 Dec 1;20(23):5918-26 - PubMed
  8. Oncologist. 2010;15(3):285-92 - PubMed
  9. Mol Cancer Ther. 2009 Jul;8(7):1867-77 - PubMed
  10. Science. 1999 May 28;284(5419):1534-7 - PubMed
  11. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  12. Br J Cancer. 2010 Jan 5;102(1):8-18 - PubMed
  13. BMC Cancer. 2006 May 02;6:110 - PubMed
  14. J Hepatol. 2014 Oct;61(4):947-50 - PubMed
  15. Cancer Res. 2010 May 15;70(10 ):4141-50 - PubMed
  16. United European Gastroenterol J. 2013 Oct;1(5):351-7 - PubMed
  17. Clin Sci (Lond). 2014 Jun;126(11):775-84 - PubMed
  18. Curr Oncol Rep. 2014 Feb;16(2):365 - PubMed
  19. Diagn Interv Radiol. 2010 Sep;16(3):186-92 - PubMed
  20. Abdom Imaging. 2005 May-Jun;30(3):324-41 - PubMed
  21. Clin Cancer Res. 2013 Mar 15;19(6):1312-4 - PubMed
  22. Cancer Med. 2014 Jun;3(3):580-91 - PubMed
  23. Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):551-60 - PubMed
  24. Hepatology. 2013 Mar;57(3):1068-77 - PubMed
  25. J Natl Cancer Inst. 2008 May 21;100(10):698-711 - PubMed
  26. Cancer Chemother Pharmacol. 2011 Feb;67(2):315-24 - PubMed

Publication Types